Free Trial

Exome Asset Management LLC Acquires New Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Viridian Therapeutics logo with Medical background

Exome Asset Management LLC bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 174,400 shares of the company's stock, valued at approximately $3,968,000. Viridian Therapeutics makes up approximately 2.7% of Exome Asset Management LLC's portfolio, making the stock its 12th biggest holding. Exome Asset Management LLC owned 0.22% of Viridian Therapeutics at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Arizona State Retirement System raised its holdings in shares of Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock valued at $171,000 after purchasing an additional 1,688 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Viridian Therapeutics by 17.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock valued at $318,000 after buying an additional 2,036 shares in the last quarter. AlphaCentric Advisors LLC lifted its holdings in Viridian Therapeutics by 20.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company's stock worth $341,000 after buying an additional 2,500 shares during the last quarter. DCF Advisers LLC boosted its position in shares of Viridian Therapeutics by 22.4% during the 2nd quarter. DCF Advisers LLC now owns 17,750 shares of the company's stock worth $231,000 after acquiring an additional 3,250 shares in the last quarter. Finally, Quest Partners LLC increased its holdings in shares of Viridian Therapeutics by 344.0% in the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company's stock valued at $79,000 after acquiring an additional 4,692 shares during the last quarter.

Viridian Therapeutics Price Performance

Shares of VRDN traded down $0.14 during trading hours on Friday, reaching $17.85. The company had a trading volume of 1,558,661 shares, compared to its average volume of 1,114,550. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20. The firm has a 50 day simple moving average of $22.04 and a 200-day simple moving average of $17.88. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -4.14 and a beta of 1.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). The company had revenue of $0.09 million during the quarter, compared to analysts' expectations of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on VRDN. HC Wainwright increased their target price on shares of Viridian Therapeutics from $27.00 to $34.00 and gave the company a "buy" rating in a research report on Thursday, November 14th. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Monday, November 25th. Royal Bank of Canada reissued an "outperform" rating and issued a $44.00 target price on shares of Viridian Therapeutics in a report on Thursday, December 5th. BTIG Research increased their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday, September 26th. Finally, TD Cowen assumed coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating on the stock. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.33.

Check Out Our Latest Analysis on VRDN

Insider Buying and Selling

In other Viridian Therapeutics news, CEO Stephen F. Mahoney purchased 21,400 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average cost of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the transaction, the chief executive officer now directly owns 21,400 shares of the company's stock, valued at $499,262. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Thomas W. Beetham acquired 5,000 shares of the business's stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $23.41 per share, with a total value of $117,050.00. Following the completion of the transaction, the chief operating officer now directly owns 6,000 shares in the company, valued at approximately $140,460. The trade was a 500.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.65% of the stock is currently owned by insiders.

Viridian Therapeutics Company Profile

(Free Report)

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

See Also

Institutional Ownership by Quarter for Viridian Therapeutics (NASDAQ:VRDN)

Should you invest $1,000 in Viridian Therapeutics right now?

Before you consider Viridian Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.

While Viridian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Home Depot: Reliable Dividends for Income Investors

Home Depot: Reliable Dividends for Income Investors

Home Depot has consistently delivered strong dividend growth, with an impressive 11.69% average annual dividend increase over the last three years.

Related Videos

Hershey’s Dividend Growth: A Sweet Pick for Investors
Inflation-Busting Dividends: 3 Stocks Raising Payouts 4X Faster

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines